Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (CGEN) is a clinical-stage cancer immunotherapy company that regularly issues news on its drug discovery platform, clinical programs, and strategic collaborations. The company emphasizes its predictive AI/ML-powered computational discovery platform, Unigen™, which it uses to identify novel drug targets and biological pathways for immuno-oncology therapies.
News about Compugen often highlights progress across its key clinical-stage assets. Updates include data and trial milestones for COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody, and COM902, a potential best-in-class Fc-reduced high-affinity anti-TIGIT antibody in Phase 1 development. The company also reports on GS-0321 (previously COM503), a potential first-in-class, high-affinity anti-IL-18 binding protein antibody licensed to Gilead, and on rilvegostomig, a PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca under license from Compugen.
Investors following CGEN news can expect coverage of clinical trial initiations and updates, such as the MAIA-ovarian platform trial evaluating COM701 maintenance therapy in relapsed platinum-sensitive ovarian cancer, pooled analyses of Phase 1 trials in platinum-resistant ovarian cancer, and first-in-human studies of GS-0321 in advanced solid malignancies. Company communications also describe partner-led studies of rilvegostomig in indications including non-small cell lung cancer and bladder cancer.
In addition, Compugen’s news flow includes quarterly financial results, cash runway commentary, amendments to collaboration agreements such as royalty monetization transactions with AstraZeneca, and participation in scientific and investor conferences. The CGEN news page on Stock Titan aggregates these announcements so readers can track clinical, financial, and partnership developments from a single source.
Summary not available.
Summary not available.
Summary not available.
Compugen Ltd. (Nasdaq: CGEN) has announced that it will present new clinical data regarding its candidate COM701 during the upcoming American Society of Clinical Oncology (ASCO) annual meeting from June 2-6, 2023, in Chicago. The data will focus on the triple combination therapy of COM701, BMS-986207 (anti-TIGIT), and nivolumab in patients with metastatic endometrial cancer. The presentation titled Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab is scheduled for June 5, 2023. This research highlights Compugen's commitment to innovative cancer immunotherapy methods.Company Background: Compugen is advancing several therapeutic programs, including COM902 and the partnered program rilvegostomig, with a focus on addressing immune resistance in cancer treatments.
Compugen Ltd. (Nasdaq: CGEN) announced the upcoming presentation of pre-clinical data on its lead asset, COM503, at the 20th CIMT Annual Meeting in Mainz, Germany, from May 3-5, 2023. COM503 is a first-in-class anti-IL18 binding protein antibody designed to inhibit cancer growth by releasing endogenous IL-18, which is crucial for activating NK and T cells in the tumor microenvironment. The company's plan includes filing an IND for COM503 in 2024.
The presentation, featuring high-affinity interactions of COM503 with IL-18 binding protein, aims to demonstrate enhanced anti-tumor activity while preserving peripheral immunity. Compugen's research highlights the potential of targeting cytokine biology in cancer treatment and positions COM503 as a transformative candidate within its broader immuno-oncology pipeline.
Compugen Ltd. (NASDAQ: CGEN) announced its upcoming presentation at the AACR annual meeting from April 14-19, 2023, in Orlando, Florida. The research focuses on the correction of the GENCODE gene model, which enables accurate detection of the novel target PVRIG. This advancement aims to enhance cancer immunotherapy research. Dr. Anat Cohen-Dayag emphasized the importance of single cell technology in understanding cancer biology. The presentation is scheduled for April 18, 2023, and will explore algorithms for gene model correction impacting PVRIG and TIGIT pathways. Compugen is advancing its product candidates, COM701 and COM902, targeting solid tumors.
Compugen Ltd. (Nasdaq: CGEN) will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:00 AM ET. The event will be held virtually, and interested parties can access a live webcast through the Investor Relations section of Compugen's website. A replay will be available for 90 days post-event. Compugen is focused on developing cancer immunotherapies, with notable candidates including COM701 and COM902. The company is headquartered in Israel and also has a presence in San Francisco, CA.
Compugen Ltd. (NASDAQ: CGEN) announced the dosing of the first patient in a proof-of-concept study evaluating a triple combination of COM701, COM902, and pembrolizumab for metastatic microsatellite stable colorectal cancer (MSS CRC). This follow-up to previous positive findings aims to assess the treatment's efficacy in patients with liver metastases who have undergone up to three lines of therapy. Initial findings are expected by the end of 2023. The study is based on earlier Phase 1 data showing anti-tumor activity with the dual combination of COM701 and nivolumab. Compugen continues to advance its immunotherapy pipeline with promising candidates.
Compugen Ltd. (CGEN) reported its financial results for Q4 and full-year 2022, highlighting significant progress in clinical studies, including upcoming triple combination studies targeting metastatic microsatellite stable colorectal cancer (MSS CRC) and platinum-resistant ovarian cancer (PROC). The company has approximately $83.7 million in cash, expected to fund operations through 2024. Revenues for Q4 were $7.5 million, increasing from $6 million in 2021. Total net loss for the year was $33.7 million. Notably, AstraZeneca's advancement of a related program triggered a $7.5 million milestone payment, validating Compugen's pipeline.
Compugen Ltd. (NASDAQ: CGEN) announced that AstraZeneca's bi-specific antibody, rilvegostomig, derived from Compugen's COM902, is set to progress into a Phase 3 trial in 2023. This trial will evaluate rilvegostomig's effectiveness as a PD-1/TIGIT bi-specific therapeutic. AstraZeneca is also expanding its Phase 2 program across various cancer indications. Compugen has received $10 million upfront and $15.5 million in milestone payments from AstraZeneca and is eligible for up to $200 million in additional milestones along with tiered royalties on future sales.